Sah Clinical Trials 2023

Sah Clinical Trials 2023

Sah research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in sah clinical trials today.

Trials for ASAH Patients

Trials for Brain Aneurysm Patients

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to sah

What are the top hospitals conducting sah research?

When it comes to the cutting-edge research and clinical trials in Subarachnoid Hemorrhage (SAH), several top hospitals are leading the way. Foothills Medical Center, located in Calgary, has emerged as a prominent player with two active SAH trials and a total of two completed studies since their first recorded trial back in 2009. Moving southward to Columbus, Ohio, we find The Ohio State University Wexner Medical Center making valuable contributions with one ongoing SAH trial and an additional two completed trials dating back to 2016.

Further west, Stanford University situated in Palo Alto continues to push the boundaries of medical innovation by currently conducting one active SAH trial while having accomplished another study previously. Interestingly enough, both institutions have made significant strides recently as they each recorded their very first SAH trial only this year (2021).

In Aurora at the University of Colorado Anschutz Medical Campus, researchers are similarly exploring new frontiers with one ongoing SAH trial alongside a single previously conducted study - both initiated this year. Meanwhile, Our Lady of the Lake Regional Medical Center in Baton Rouge also joins this group as they actively participate in one clinical trial for SAH while having successfully completed another investigation.

These healthcare facilities serve patients not only within their local communities but also attract individuals seeking advanced medical care from across the nation. Together these institutions illustrate that progress is being made through dedicated efforts and groundbreaking research towards understanding and treating Subarachnoid Hemorrhage events—bringing hope to patients affected by this condition worldwide.

Which are the best cities for sah clinical trials?

In the realm of SAH (subarachnoid hemorrhage) clinical trials, several cities have emerged as hotspots for research and innovation. Nashville, Tennessee leads the pack with 4 ongoing trials investigating treatments like N-acetylcysteine and acetaminophen. Baltimore, Maryland follows closely behind with 3 active studies focused on interventions such as Neuromuscular Electrical Stimulation (NMES), Integrated AUD Treatment, and Docosahexaenoic Acid. Additionally, San Antonio, Texas; Durham, North carolina; and Boston Massachusetts each contribute to advancing SAH care through their respective active trials exploring a range of potential treatments. These cities serve as hubs of medical progress in the field of subarachnoid hemorrhage clinical research.

Which are the top treatments for sah being explored in clinical trials?

Clinical trials exploring treatments for subarachnoid hemorrhage (SAH) have highlighted some promising options. The CerebroFloâ„¢ EVD Catheter, introduced in 2021, is currently being tested in one active SAH trial and has shown potential as a therapeutic approach. Another innovative treatment is auricular vagus nerve stimulation, which also made its debut in 2021 and is under investigation in one ongoing SAH trial. Furthermore, the regional anesthetic SPG block-bilateral technique, listed since 2020, offers another avenue of exploration with its involvement in one active SAH trial. These cutting-edge treatments hold promise for improving outcomes for patients affected by this condition.

What are the most recent clinical trials for sah?

Exciting developments are occurring in the field of subarachnoid hemorrhage (SAH) with recent clinical trials offering potential advancements in treatment. One such trial involves the use of deferoxamine, a medication being investigated in Phase 2 studies for SAH patients. Another study explores the continuous administration of antibiotics until an external ventricular drain is removed, aiming to improve outcomes after SAH. Additionally, Phase 1 trials have examined regional anesthetic SPG block-bilateral and deferiprone pills as potential interventions for SAH. Although these trials are still ongoing or at early stages, they represent significant steps towards enhancing patient care and management following SAH events.

What sah clinical trials were recently completed?

In recent years, several clinical trials focusing on subarachnoid hemorrhage (SAH) have come to fruition, bringing new insights and advancements in the field. Notably, a trial sponsored by the University of Wisconsin, Madison investigated the potential of Acetazolamide and concluded in July 2019. Similarly, Idorsia Pharmaceuticals Ltd. conducted a trial testing Clazosentan with SAH patients, completing their study in December 2018. These completed trials contribute valuable data to inform future approaches for SAH treatment and underline ongoing efforts to improve outcomes for individuals affected by this condition.